1
Return

Treatment Trajectories and Dose Optimization of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A Real-World Landmark Analysis

delete2026-06-26
delete0
PRE
AI
C
Chiara Palagiano
C
Cataldo Patruno *
M
Martina Turco
F
Francesca di Vico
L
Luca Potestio
DOI：10.1093/ced/llag271delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Abrocitinib is an effective oral Janus kinase 1 inhibitor for moderate-to-severe atopic dermatitis (AD), although real-world evidence regarding dose optimization strategies remains limited.

Journal

Clinical and Experimental Dermatology cover
Clinical and Experimental Dermatology
IF:
2.8
Papers:
9.0K
Citations:
6.7K

Organization

U
university of molise
Scholars:
487
Papers: 234
Citations: 0
U
University of Naples Federico II
Scholars:
4.6W
Papers: 3.6W
Citations: 51
Cited Papers

Cited Papers

Citing Papers

Citing Papers